SCHEDULE: KCK Ltd. & Nael Kassar Report 7% Stake in Sight Sciences

KCK Ltd. and Nael Karim Kassar have reported a 7.0% beneficial ownership stake in Sight Sciences, Inc., holding 3,706,914 common shares.

Summary

• KCK Ltd. and Nael Karim Kassar collectively beneficially own 3,706,914 shares of Sight Sciences, Inc. Common Stock.
• This ownership represents 7.0% of the total class of securities outstanding.
• The ownership percentage is calculated based on 52,871,731 shares of Common Stock outstanding as of October 31, 2025, as reported in Sight Sciences, Inc.'s Quarterly Report on Form 10-Q.
• Both KCK Ltd. and Nael Karim Kassar hold shared voting power and shared dispositive power over these 3,706,914 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it confirms a significant and continued institutional stake in Sight Sciences, Inc., which can be interpreted as a vote of confidence by a major investor.

Positives

• Significant institutional ownership by KCK Ltd. and Nael Karim Kassar, representing 7.0% of the company's common stock.
• Continued investment by a substantial shareholder group may signal confidence in Sight Sciences, Inc.'s long-term prospects.

Negatives

• No specific negative information is disclosed in this beneficial ownership statement.

Risks

• No specific risks related to Sight Sciences, Inc. are detailed in this Schedule 13G filing.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Sight Sciences, Inc.'s future performance or strategic direction.

Management Comments

• This filing does not contain direct quotes or paraphrased statements from Sight Sciences, Inc. management. It includes signatures from KCK Ltd.'s Secretary and Nael Karim Kassar as Founder and Chief Executive Officer of KCK Ltd.

Industry Context

StockSavvy.ai notes that significant beneficial ownership filings like this Schedule 13G can indicate sustained institutional interest in companies within the medical device and ophthalmology sectors. While this filing primarily discloses ownership, the continued holding by a substantial investor group like KCK Ltd. and Nael Karim Kassar suggests a long-term view on Sight Sciences, Inc.'s market position and product pipeline, potentially influencing broader investor sentiment in the specialized healthcare industry.

Comparison to Industry Standards

• This filing is a disclosure of beneficial ownership and does not provide performance metrics or operational results that can be directly compared to industry standards or specific competitor projects. It solely details the ownership stake of KCK Ltd. and Nael Karim Kassar in Sight Sciences, Inc.

Management Changes

Corporate Governance

Legal Proceedings

• This filing does not disclose any information regarding legal proceedings or regulatory matters concerning Sight Sciences, Inc. or the reporting persons.

Related Party Transactions

• This filing does not disclose any related party transactions involving Sight Sciences, Inc.

Stakeholder Impact

• Shareholders: May view the continued significant ownership by KCK Ltd. and Nael Karim Kassar as a positive indicator of long-term value and stability.
• Potential Investors: Could interpret the substantial institutional stake as a sign of confidence, potentially attracting further investment.

Next Steps

• The filing does not outline any specific future actions, events, or milestones for Sight Sciences, Inc. or the reporting persons beyond the regulatory disclosure itself.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of a significant beneficial ownership stake by KCK Ltd. and Nael Karim Kassar. While the 7.0% ownership indicates a substantial and continued investment, the filing itself does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The sustained institutional interest is generally a positive signal, suggesting a 'hold' position for existing investors and a neutral stance for potential new investors pending further fundamental analysis.

Keywords

Sight Sciences, KCK Ltd., Nael Karim Kassar, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Medical Devices, Ophthalmology